NCT00287352View on ClinicalTrials.gov

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Psychotic DisorderSchizophreniform DisorderSchizophreniaSchizoaffective DisorderMood Disorders With Psychotic Features
Interventions
DRUG

Olanzapine, Amantadine

Olanzapine continuing as clinically indicated, Amantadine 100 mg tid

DRUG

Olanzapine and placebo

Olanzapine continuing as clinically indicated

Trial Locations (1)

27599

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT00287352 - Study of Amantadine for Weight Stabilization During Olanzapine Treatment | Biotech Hunter | Biotech Hunter